Search results
Your search for ultram returned no results
Showing 16 to 30 of 42 results for ultra
Showing 16 to 30 of 42 results for ultra
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)
Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)
This guidance has been updated and replaced by NICE interventional procedures guidance 757.
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTE26)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease....
View recommendations for HTE26Show all sections
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTE33)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards....
View recommendations for HTE33Show all sections
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic